DIGITAL-VAULT-SERVICES
15.4.2024 09:01:30 CEST | Business Wire | Press release
Digital Vault Services:
- Siemens chooses Digital Vault Services (DVS) for guarantee digitization.
- Collaboration with Digital Vault Services reflects Siemens commitment to innovation and efficiency.
- DVS’s Guarantee Vault Platform enables Siemens to optimize workflow efficiency and enhance security in guarantee management.
Siemens, a technology company focused on industry, infrastructure, transport, and healthcare, chooses Digital Vault Services for guarantee digitization, reflecting its dedication to innovation and efficiency. Through the integration of Digital Vault Services' innovative Guarantee Vault Platform (GVP), Siemens propels its digital transformation journey within its Guarantee Business, leveraging technology to optimize operations and enhance customer satisfaction.
The adoption of the Guarantee Vault will empower Siemens for streamlined and digitized guarantee processes. With GVP integrated into its operations, Siemens will benefit from GVP’s unchallenged capabilities to seamlessly connect to the entire guarantee ecosystem including all bank and insurance partners.
Gerhard Heubeck, Global Head Trade Finance Advisory at Siemens, commented, “We are pleased to announce our partnership with Digital Vault Services. As an active member of the working group, we have always been convinced of GVP's capabilities to significantly improve our collaboration and communication with our financial partners and to eliminate time-consuming, manual and paper-based processes. By leveraging GVP's innovative features, we can now engage in efficient, fast, and paperless interactions, while fully digitizing the end-to-end process from our organization through our financial partners to our valued customers. “
"We are thrilled to collaborate with Siemens, a key member of the working group that contributed to the development of our Guarantee Vault Platform," said Ludger Janßen, Co-CEO of Digital Vault Services. "Siemens commitment to innovation aligns perfectly with our mission to digitize the entire guarantee ecosystem and helps with the digital transformation of the financial industry. Together, we will drive significant advancements in guarantee processing efficiency and security."
Jaime Gimeno, Co-CEO of Digital Vault Services added: "With digital guarantees issued, secured and safekept on Guarantee Vault, Siemens and its customers are well positioned to achieve maximum efficiency and transparency. We do all this using best in class technology secured to ISO 27001 standards to keep our customers safe. We welcome Siemens to our network and look forward to working with them on their digitization journey."
About Digital Vault Services
Digital Vault Services GmbH revolutionizes the guarantee journey with its Guarantee Vault, boosting complete digitization. This solution offers a seamless, paperless experience, transforming the guarantee ecosystem end to end. Applicants can request all types of guarantees globally within one central tool, while banks and insurers securely issue and store guarantees. Beneficiaries enjoy seamless interaction and can manage and access the guarantees anytime. Innovative features such as beneficiary read confirmation and pre-approved wording libraries enhance processing speed, transparency, and efficiency. With top-tier security standards and API integration for seamless connectivity, DVS ensures a robust solution for all guarantee- business needs.
Founded in 2018 through collaboration with 16 industry participants, banks and insurers, Digital Vault Services has rapidly evolved. Since its launch in 2021, Guarantee Vault has gained strong traction in Germany and is now expanding into other European markets, including the Nordic countries, where future presence has already been announced. The company’s headquarters are located in Munich, Germany.
About Siemens
Siemens AG (Berlin and Munich) is a leading technology company focused on industry, infrastructure, transport, and healthcare. From more resource-efficient factories, resilient supply chains, and smarter buildings and grids, to cleaner and more comfortable transportation as well as advanced healthcare, the company creates technology with purpose adding real value for customers. By combining the real and the digital worlds, Siemens empowers its customers to transform their industries and markets, helping them to transform the everyday for billions of people. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a globally leading medical technology provider shaping the future of healthcare. In fiscal 2023, which ended on September 30, 2023, the Siemens Group generated revenue of €77.8 billion and net income of €8.5 billion. As of September 30, 2023, the company employed around 320,000 people worldwide. Further information is available on the Internet at www.siemens.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240412273459/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom